Upsurge in consumption in low and middle-income countries (LMICs), increase in prevalence of infectious diseases, and adoption of novel approaches for treatment of bacterial infections drive the ...

Please provide your email address to receive an email when new articles are posted on . A metallo-beta-lactam inhibitor could help fight resistance to beta-lactam antibiotics. MK-3402 was found to be ...

Please provide your email address to receive an email when new articles are posted on . Using Clinical and Laboratory Standards Institute, or CLSI, revised breakpoints and omitting extended-spectrum ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated ...

Pfizer has just completed phase 3 trials of a new antibiotic that's active against highly resistant Gram-negative infections. It's a real superbug fighter. But what took so long? Once upon a time in a ...

Roche has obtained rights from Meiji Seika Pharma (Meiji) and Fedora Pharmaceuticals to develop and commercialize the Phase I beta-lactamase inhibitor OP0595 worldwide except Japan, as part of a ...

Paris, France, 22 January 2008 -- Novexel, the pharmaceutical company focused on the discovery and development of novel antibacterials and anti-fungals, today announces that it has entered into an ...

Staphylococcus aureus is the S in ESKAPE, an acronym for the six bacteria that are considered the greatest threats to public health by the Infectious Disease Society of America. Like the rest of the ...

While beta-lactams kill bacteria by binding to PBPs, bacteria evolved to produce beta-lactamases which inactivate these agents. Entasis’ non-beta-lactam PBP inhibitors are unaffected by all four ...

WHITEHOUSE STATION, N.J.--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated relebactam (previously ...